• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 68Pharmacological treatment discontinuation due to side effects: findings of the network meta-analysis and of classical pair-wise comparisons versus placebo

DrugNetwork meta-analysis (results for 8 weeks)Classical pair-wise meta-analysis
Probability (Pr) of discontinuation due to side effects (95% credible interval - CrI)Pr that drug is best in averting discontinuation due to side effectsPr that drug is best in averting discontinuation due to side effects (excluding placebo)Hazard ratio (HR) versus placebo (95% CrI)RR versus placebo (95% CI)
Placebo0.058 (0.014, 0.161)0.549
Sertraline0.072 (0.013, 0.237)0.3380.6061.24 (0.60, 2.35)1.10 (0.63, 1.91)
Pregabalin0.086 (0.017, 0.256)0.0620.2231.48 (1.06, 2.01)1.31 (0.99, 1.74)
Escitalopram0.094 (0.018, 0.275)0.0470.1451.62 (1.09, 2.36)1.72 (1.16, 2.53)
Paroxetine0.135 (0.029, 0.381)0.0030.0152.41 (1.72, 3.37)2.50 (1.81, 3.45)
Venlafaxine XL0.142 (0.031, 0.395)0.0010.0082.55 (1.97, 3.32)2.06 (1.59, 2.68)
Duloxetine0.175 (0.037, 0.475)0.0000.0033.26 (2.15, 4.84)3.12 (1.55, 6.31)


Cover of Generalised Anxiety Disorder in Adults
Generalised Anxiety Disorder in Adults: Management in Primary, Secondary and Community Care.
NICE Clinical Guidelines, No. 113.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2011.
Copyright © 2011, The British Psychological Society & The Royal College of Psychiatrists.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.